Posts By: pharmanewsdaily

BioTheryX begins BTX-A51 phase 1 trial in AML and myelodysplastic syndrome

BTX-A51 phase 1 trial : US biotech company BioTheryX has initiated patient dosing in its first clinical program of its small molecule BTX-A51 in patients having relapsed/refractory acute myeloid leukemia (AML), and also in high-risk myelodysplastic syndrome patients. The phase 1 clinical trial of BTX-A51 will assess the safety, pharmacokinetics, and tolerability of the oral […]

Frazier Healthcare Partners raises $617m for life sciences fund

Frazier Healthcare Partners has closed its third life sciences fund – Frazier Life Sciences X, at more than $617 million in capital commitments. The Seattle-based private equity and venture capital firm has been investing in life sciences since more than 29 years ago Since its inception, Frazier Healthcare Partners has raised its total committed capital to approximately $4.8 […]

Arena Pharmaceuticals’ APD418 gets FDA fast track status in decompensated heart failure

Arena Pharmaceuticals has secured that fast track designation for its drug candidate APD418 from the US Food and Drug Administration (FDA) for the treatment of decompensated heart failure (DHF). APD418 is a β3-adrenergic receptor (AdrR) antagonist and cardiac myotrope. According to the San Diego-based biopharma company, APD418 is a selective antagonist that has been designed […]

Cerevel launches phase 3 Parkinson’s disease clinical trials for tavapadon

Parkinson’s disease clinical trials : Cerevel Therapeutics, a US biopharma company, has initiated a phase 3 clinical trial program for evaluating tavapadon in Parkinson’s disease patients, as per the latest clinical trial news. Tavapadon is being developed as an orally-bioavailable, selective partial agonist of the dopamine D1 and D5 receptors, and is being assessed for […]

Alexion discloses plan for CHAMPION-ALS clinical trial of ULTOMIRIS

Alexion Pharmaceuticals has revealed plans for initiating the CHAMPION-ALS clinical trial, a phase 3 study to evaluate ULTOMIRIS (ravulizumab) for the treatment of amyotrophic lateral sclerosis (ALS). The late-stage clinical trial, which will be held globally by the US pharma company for 50 weeks, will feature nearly 350 adults across a broad patient population. The […]

NeuroBo, Gemphire merger wrapped up to form neurodegenerative disease company

NeuroBo Pharmaceuticals,  a Boston-based clinical-stage pharma company, has wrapped up its previously announced merger with Gemphire Therapeutics, a Michigan-based clinical-stage biopharma company focused on developing therapies for dyslipidemia and nonalcoholic fatty liver disease (NASH). The new combined company will be called NeuroBo Pharmaceuticals, which will focus on advancing a clinical-stage pipeline targeting neurodegenerative diseases. NeuroBo, […]

TERN-201 NASH clinical trial : Terns reports positive results for phase 1 study

TERN-201 NASH clinical trial : Terns Pharmaceuticals said that an ongoing phase 1 trial of its semicarbazide-sensitive amine oxidase (SSAO) inhibitor TERN-201 in non-alcoholic steatohepatitis (NASH) has yielded positive results. According to the US biopharma company, the early-stage NASH clinical study showed that a single oral dose of TERN-201 delivered a sustained, near-complete suppression of […]

Taro recalls lot of Lamotrigine tablets in US due to contamination

Taro Pharmaceuticals U.S.A. has issued to recall of a lot of Lamotrigine 100 mg tablets owing to cross-contamination with a trace of another drug substance – Enalapril Maleate. Lamotrigine is indicated for the treatment of epilepsy and bipolar disorders. The US pharmaceutical manufacturer is recalling Lot # 331771, which has an expiration date June 2021 […]

PACT Pharma raises $75m to develop neoTCR-T cell therapies for solid tumors

PACT Pharma, a California-based clinical stage company, which is focused on developing fully personalized neoTCR-T cell therapies for solid tumors, has raised $75 million in a Series C financing round. The funding round was led by Vida Ventures, a life science venture firm, with participation from the current investors of PACT Pharma. The clinical stage […]

Scroll To Top